 H.C. Wainwright initiated coverage of Gemini Therapeutics Inc NASDAQ: GMTX with a Buy rating and 20 price target. In the near term, the expected Phase 2a readout for lead asset GEM103 can serve as a platform catalyst, analyst Matthew Caufield tells investors in a research note. 